CCChong Chen

Chong Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chong Chen has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Baocheng Gong

    Department of Pediatric Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer

    3 shared publications
  • Feng He

    Academy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, China

    3 shared publications
  • Haiyang Zhang

    Tianjin Institute of Coloproctology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, China

    3 shared publications
  • Jie Hao

    Department of Thyroid and Breast Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, China

    3 shared publications
  • Lin Liu

    Department of Clinical Laboratory, Tianjin Union Medical Center, Nankai University

    3 shared publications
  • Tiantian She

    School of Medical Laboratory, Tianjin Medical University

    3 shared publications

Latest Publications

  • Open Access

    Bone marrow CD14+CD206+ M2-like monocyte-macrophages as a potential complementary biomarker for bone marrow MRD in high-risk neuroblastoma

    by Xiaoyan Hu, Lin Liu, Yuge Ni, Chen Huang, Yan Jin, Baocheng Gong, Tiantian She, Chong Chen

    Neuroblastoma (NB) is a highly aggressive pediatric malignancy, frequently associated with a substantial risk of bone marrow metastasis and recurrence. The persistence of minimal residual disease (MRD) remains the primary obstacle to successful treatment outcomes. Bone marrow minimal residual disease (MRD) assessment in high-risk neuroblastoma primarily relies on the direct detection of residual tumor cells. However, the accompanying immune-microenvironmental changes remain incompletely characterized. In this study, GD2-directed immunocytochemistry, complemented by GD2-based flow cytometry, was used for the reference classification of bone marrow disease status in a cohort of 143 patients with high-risk neuroblastoma. We evaluated a panel of peripheral blood biomarkers, identifying NSE, CRP, FBG, and D-dimer as exhibiting significant differences between MRD-positive and MRD-negative groups; however, these biomarkers demonstrated limited diagnostic utility, with area under the curve (AUC) values below 0.7. Importantly, bone marrow CD14 + CD206 + M2-like monocyte-macrophages showed discriminatory ability for GD2-defined bone marrow MRD status (AUC = 0.794), with an optimal threshold of 1.71×10 4 /mL. Additionally, the proportion of CD14 + CD206 + macrophages showed a positive correlation with GD2 positivity in bone marrow samples. These findings suggest that bone marrow CD14 + CD206 + M2-like monocyte-macrophages showed potential as an auxiliary immune biomarker associated with bone marrow MRD status in high-risk NB. These findings require validation in larger, independent cohorts.

  • Open Access

    Associations between legacy and emerging per and polyfluoroalkyl substances (PFAS) bioaccumulation and clinicopathological characteristics in breast cancer

    by Bei Sun, Zhanhua Gao, Xiyue Liu, Gexue Liu, Shoujun Wang, Jinpu Liu, Junyi Wang, Haiyang Zhang, Mingqing Zhang, Chong Chen, et al.

    Inroduction: Per and polyfluoroalkyl substances (PFAS) are persistent environmental contaminants with endocrine-disrupting and carcinogenic potential. However, their bioaccumulation profiles and clinical relevance in human breast cancer remain largely unexplored. Methods: In this preliminary study we quantified the absolute concentrations of 33 PFAS congeners (ng/g) in paired tumour and adjacent non-tumorous tissues from 11 breast cancer patients ( n = 11) using LC–MS/MS to evaluate their tissue distribution and clinical correlations. Results: The detection rates for six compounds (HFPOTA, PFOA, PFNA, PFUnDA, PFOS, and 6:2Cl-PFESA) were greater than 40%. In paired samples, several congeners showed higher concentrations in tumour than in adjacent non-tumorous tissue; using a two-sided exact Wilcoxon signed-rank test with Hodges–Lehmann effect sizes, tumour enrichment remained significant after Benjamini–Hochberg correction for HFPOTA ( q = 0.041), PFNA ( q = 0.047) and PFUnDA ( q = 0.047). HFPOTA showed by far the highest tissue burden (median 654 ng/g). Clinically, PFOS concentrations were descriptively higher in Luminal B than in Luminal A tumours and were positively correlated with the proliferation marker Ki-67; a high 6:2Cl-PFESA–PR rank correlation was observed in four samples but was not statistically significant on the raw p-value (p ≈ 0.051) and is exploratory. Bioinformatic analyses indicated that computationally predicted shared target genes of PFAS and breast cancer are enriched in the PPAR signaling pathway, lipid metabolism, and steroid hormone biosynthesis. Discussion: Collectively, PFAS bioaccumulation was associated with breast cancer clinicopathological characteristics. Because the target genes are predicted rather than experimentally validated and the cohort is small ( n = 11), these are exploratory, hypothesis-generating findings that require validation in larger cohorts. This study underscores the need to reassess the biosafety of novel PFAS alternatives and provides new insights into the environmental etiology of breast cancer.

  • Differential distribution of microplastics in breast cancer and peritumoral tissues and relationship with clinical characteristics

    by Bei Sun, Jinpu Liu, Xinyi Wen, Dongzhi Hu, Zhanhua Gao, Minghan Qiu, Shoujun Wang, Zhansheng Jiang, Mingqing Zhang, Chong Chen, et al.

    The distribution characteristics of microplastics (MPs) in paired breast cancer tumor and para-tumor tissues, and their potential associations with clinical characteristics, remain insufficiently understood. This study included eight breast cancer patients with surgical resection whose paired tumor and para-tumor tissues were collected. The morphologies, particle sizes, and types of microplastics within the tissues were identified and characterized using Laser Direct Infrared (LDIR) spectroscopy and Scanning Electron Microscopy (SEM). Moreover, correlations between microplastic abundance and patients' demographic and clinical characteristics were analyzed. SEM imaging revealed diverse morphologies-granular, fibrous, and irregular-often exhibiting folds and fractures. The majority of microplastic particles were within the 20-100 μm size range. Multiple types of polymeric microplastics-including Fluororubber (Flu), polyethylene (PE), polyethylene terephthalate, polypropylene, and polyvinyl chloride (PVC)-were detected in all paired samples. Notably, the abundance of Flu, PE, and PVC was significantly higher in tumor tissues compared to para-tumor tissues. Correlation analyses identified exploratory associations between selected microplastic types, body mass index, and certain tumor biomarkers. These findings provide preliminary evidence of tissue-specific MP distribution in breast cancer and support further investigation into the potential biological relevance of microplastics in breast cancer.


  • Open Access

    TFAP2D drives neuroblastoma progression: a disulfidptosis-fatty acid metabolism-based molecular subtyping and prognostic model

    by Xiaoying Li, Baocheng Gong, Tongyuan Qu, Yan Jin, Chong Chen, Qiang Zhao

    Neuroblastoma (NB) is recognized as the predominant extracranial malignant solid tumor in children and adolescent; the prognosis for high-risk patients remains poor. This limitation stems from its low mutational burden, an absence of antigen-presenting molecules, and vascular irregularities, which collectively impede immune cell infiltration, characterizing NB as a prototypical “cold tumor”. Intriguingly, metabolic pathways, especially through a novel glucose-dependent cellular death mechanism termed disulfidptosis and fatty acid metabolism (FAM), are pivotal in modulating the tumor’s energy dynamics and activating the tumor microenvironment (TME). Therefore, this study aims to explore the prognostic value and immunological implications of disulfidptosis-related fatty acid metabolism (DFAM) within the NB TME. To elucidate the implications of DFAM within the NB TME, this research included 971 NB patients. By using weighted gene co-expression network analysis (WGCNA), we constructed a prognostic risk score model based on DFAM, aimed at enhancing prognostication accuracy and informing therapeutic choices. The biological role of TFAP2D was validated in SK-N-AS and SK-N-BE2 cells via Cell Counting Kit-8 (CCK-8) assay, wound healing, and Transwell. Two distinct novel molecular subtypes were identified, revealing the correlations between DFAM and clinical-pathological features, prognostic outcomes, and TME infiltration patterns. The DFAM risk score model was established as an independent prognostic factor, correlated with immune cell infiltration and immunotherapeutic response. A novel discovery was the inhibitory effect of TFAP2D downregulation in NB cells on cellular survival, migration, and invasion. This research demonstrates that the crosstalk between DFAM and immune cells plays an important role in forming the “cold” TME of NB. The construction of DFAM-related score and the identification of a novel molecular subtype significantly contribute to the evolution of immunotherapeutic strategies. Furthermore, the discovery of TFAP2D as a metabolic driver of tumor progression provides a potential target to disrupt the metabolic plasticity of high-risk NB.


  • Open Access

    Targeting CLIC6 with theaflavin enhances radiotherapy sensitivity in ER+/HER2− breast cancer

    by Mengying Suo, Lin Liu, Tiantian She, Chong Chen

    Background: Radiotherapy is a cornerstone of breast cancer treatment; however, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) tumors frequently exhibit intrinsic radioresistance. Understanding the molecular mechanisms underlying this resistance is crucial for improving therapeutic outcomes. This study aims to identify key molecular determinants of intrinsic radioresistance in ER+/HER2− breast cancer and to explore potential radiosensitization strategies targeting these determinants. Methods: We integrated single-cell RNA sequencing (scRNA-seq) data from ER+/HER2− breast tumors before and after radiotherapy with transcriptomic profiles from The Cancer Genome Atlas (TCGA). A high-dimensional weighted gene co-expression network analysis (hdWGCNA) was employed to identify gene modules associated with clinical traits. Functional assays were conducted in ER+ breast cancer cells with chloride intracellular channel 6 (CLIC6) overexpression or knockdown. A molecular docking analysis revealed that theaflavin specifically interacts with CLIC6. Further, clonogenic assays and Cell Counting Kit-8 (CCK-8) proliferation assays were performed to validate the biological effects of theaflavin and CLIC6 following radiotherapy. Results: The hdWGCNA identified a luminal A-like gene module correlated with progesterone receptor (PR) positivity and low Ki67 expression, within which CLIC6 emerged as a key hub gene. Elevated CLIC6 expression enhanced radioresistance, whereas CLIC6 knockdown increased radiosensitivity. Molecular docking confirmed that theaflavin binds to CLIC6 with high affinity (binding energy −8.8 kcal/mol). Theaflavin treatment significantly enhanced radiosensitivity in wild-type and CLIC6-overexpressing cells but had no effect in CLIC6-knockdown or ER-negative (ER−) cells. Conclusions: This study identified CLIC6 as a novel gene associated with radioresistance in ER+/HER2− breast cancer and showed that theaflavin functions as a natural radiosensitizer in a CLIC6-dependent manner, consistent with its high-affinity interaction with CLIC6. Targeting CLIC6 may provide a promising strategy to enhance radiotherapy efficacy in this common breast cancer subtype.


  • Open Access

    Bone marrow aspirate Cit-H3 was identified as a novel biomarker of minimal residual disease in neuroblastoma

    by Mengxia Zhang, Xiang Wang, Lin Liu, Yuge Ni, Yuanyuan Zhang, Xiaoyan Hu, Chen Huang, Baocheng Gong, Tiantian She, Chong Chen

    Background: Neuroblastoma (NB) is the most prevalent extracranial solid tumor in children. Neutrophils release neutrophil extracellular traps (NETs) following intense or prolonged activation. Neutrophil elastase (ELA2) and citrullinated histone H3 (Cit-H3) are specific markers of NETs. Additionally, neuron-specific enolase (NSE) serves as a biomarker and can be used to monitor the condition of NB progression, assess treatment response, and predict recurrence. Methods: This study employed a retrospective study design, and all samples were collected prior to bone marrow aspiration for diagnosis. A total of 39 serum samples from patients diagnosed with NB by postoperative pathological bone marrow aspiration were included as the study subjects, and neutrophils, ELA2, and Cit-H3 were detected in the study subjects using ELISA. The blood routine data of 99 patients diagnosed with NB were collected, and these data were from patients different from those of the aforementioned 39 serum samples. And patients were divided into two groups, namely NB patients with positive bone marrow metastasis and those without metastasis, based on the result of bone marrow GD2 immunohistochemical staining. All data were statistically analyzed using IBM SPSS Statistics 26.0 and GraphPad Prism 9.0 software. Results: A positive correlation was identified between NB bone marrow minimal residual disease (MRD) positivity and haematological indices, including interleukin-2 (IL-2) ( p = 0.021), IL-6 ( p = 0.030), NSE ( p < 0.001), and Cit-H3 ( p < 0.001). And MRD was positively associated with blood neutrophils in bone marrow ( p < 0.05). Conclusions: This study demonstrates a significant correlation between NETs and MRDs, and found a positive correlation between bone marrow MRD + and the indicators of IL-2, IL-6, and NSE, as well as a positive correlation with bone marrow neutrophils. And Cit-H3 was identified as a new biomarker and found a positive correlation between Cit-H3 and bone marrow MRD + .


  • Comparative analysis of engineered-exosome delivered si-HER2 and trastuzumab in the treatment of HER2-positive gastric cancer

    by Yuehong Zhu, Yaoyang Guo, Ziyi Dong, Mingqing Zhang, Hui Liu, Xinyi Wen, Wenwen Pang, Xipeng Zhang, Zhansheng Jiang, Chong Chen, et al.

    Summary Trastuzumab is currently a key targeted drug for HER2-positive gastric cancer (GC), but there are common problems of drug resistance and cardiotoxicity in clinical treatment, resulting in poor therapeutic effects. Exosomes are natural nanocarriers for drug delivery and engineered exosomes have been widely used in translational medicine research. This study is designed to compare the anti-tumor effects and adverse effects between engineered exosomes carrying HER2 siRNA and trastuzumab. The stable cell line of iRGD-293T was constructed by using lentiviruses, and iRGD-293T and 293T cells were transfected with si-HER2 and exosomes were isolated by ultra-centrifugation. Functional experiments were performed to examine the inhibitory effects of iRGD-exo-si-HER2 and trastuzumab on both HER2-positive GC cells and mouse xenograft models. Blood biochemical indexes were used to test the adverse effects, especially cardiotoxicity. The engineered exosomes modified by iRGD peptide showed higher tumor affinity compared to control exosomes in vitro and in vivo. si-HER2 delivered by iRGD-exosomes significantly inhibited the proliferation and promoted apoptosis of HER2-positive GC cells, and iRGD-exo-si-HER2 significantly reduced the expression of HER2 in GC cells in vitro and in vivo, showing similar efficacy as trastuzumab but with lower cardiac side effects. Our data indicated that iRGD-exo-si-HER2 shows good anti-tumor effect both in vivo and in vitro, and has fewer side effects compared with trastuzumab. And this study suggested that engineering exosomes with si-HER2 can serve as novel strategy for the treatment of HER2-positive GC. Graphical Abstract


  • Open Access

    Multiplexed Electrochemical Sensing of Single-Nucleotide Polymorphic MicroRNAs in Liver Cancer

    by Gabriel Sasa, Chong Chen, Baixun He, Wenxin Zhang, Allen Borlay, Cherie Tan, Dong Ming

    Liver cancer remains a highly lethal malignancy, primarily due to the limitations of current biomarkers like α-fetoprotein (AFP), which fails to detect many early-stage cases. MicroRNAs (miRNAs) have emerged as promising diagnostic biomarkers, particularly those influenced by single-nucleotide polymorphisms (SNPs). However, conventional electrochemical biosensors for miRNA detection often require complex probe modifications to achieve sufficient sensitivity and selectivity. Here, we present a multiplex electrochemical biosensor for the simultaneous detection of SNP-associated miRNAs (SNP-146a and SNP-122) linked to liver cancer. The biosensor leverages amino-rich polyethyleneimine gold nanoparticles (PEI-AuNPs) to immobilize capture and signal probes efficiently, enabling robust signal amplification. Using metal ion tags (Pb²⁺ for SNP-146a and Ag⁺ for SNP-122) and differential pulse voltammetry (DPV), we achieved distinct, highly sensitive detection with limits of detection (LODs) of 0.39 pM and 0.23 pM, respectively, across a broad linear range (1 pM–100 nM). Clinical validation using serum samples yielded statistically significant discrimination (P = 0.0013 for SNP-146a, P = 0.0001 for SNP-122) and outstanding diagnostic performance (ROC-AUC = 0.98 and 0.96, respectively). Meanwhile, the platform’s versatility was further demonstrated by detecting miR-181a and miR-155 with exceptional LODs (0.34 pM and 0.02 pM). This multiplexed biosensor provides a powerful tool for early liver cancer diagnosis and can be readily adapted for other tumor biomarkers, advancing precision point-of-care diagnostics.

  • Top Cited Papers
    Open Access

    Identification and analysis of microplastics in peritumoral and tumor tissues of colorectal cancer

    by Wen Pan, Jie Hao, Mingqing Zhang, Hui Liu, Fei Tian, Xipeng Zhang, Zhansheng Jiang, Chong Chen, Ming Gao, Haiyang Zhang

    The widespread occurrence of microplastics (MPs) in the environment has raised significant concerns regarding their potential health impacts, particularly in relation to carcinogenesis. This study aimed to identify and analyze microplastics present in peritumoral and tumor tissues of patients diagnosed with colorectal cancer (CRC). Utilizing advanced scanning electron microscopy (SEM) and laser direct infrared (LDIR) imaging systems, we systematically examined tissue samples to detect and characterize the microplastics. Our findings revealed a diverse array of microplastic types, notably polyvinyl chloride (PVC) and polyethylene (PE), within both peritumoral and tumor regions. Compared to adjacent non-cancerous tissues, tumor tissues exhibited a greater variety and distribution of microplastics. Furthermore, Clathrin—a key protein involved in endocytosis—was found to be highly expressed in colorectal cancer specimens, facilitating the substantial uptake of microplastics. These results suggest a potential association between exposure to microplastics and the pathogenesis of colorectal cancer. This study highlights the urgent need for increased awareness and regulatory measures aimed at mitigating microplastic pollution along with its associated health risks.


  • Open Access

    Mechanisms and molecular characterization of relapsed/refractory neuroblastomas

    by Chong Chen, Zixuan Wei

    Relapsed/refractory neuroblastoma is a type of malignant solid tumor with a very poor prognosis in children. Its pathogenesis is complex, involving multiple molecular pathways and genetic alterations. Recent studies have shown that MYCN amplification, ALK mutation, TERT promoter mutation, p53 pathway inactivation, and chromosomal instability are the key mechanisms and molecular characteristics of relapsed/refractory neuroblastoma. Precision treatment strategies targeting these molecular mechanisms have shown certain prospects in preclinical studies and clinical practice. This review focuses on the relevant mechanisms and molecular characteristics of relapsed/refractory neuroblastoma, explores its relationship with treatment response and clinical prognosis, and briefly introduces the current treatment strategies to provide a theoretical basis for the development of novel and personalized therapeutic regimens to improve the prognosis of children.